Rezkalla S, Khatib R, Khatib G, Smith F, Walsh M, Sowers J, Kloner R
Department of Internal Medicine, Harper Hospital, Detroit, MI 48201.
J Lab Clin Med. 1988 Jul;112(1):118-21.
Previous studies have shown that indomethacin administered during the early phase of experimental myocarditis may exacerbate the disease process. It is unknown whether late administration of this agent is safe. Therefore, the effect of indomethacin administration during the late phase of coxsackievirus B3 murine myocarditis was investigated. Forty 3-week-old CD1 mice each received a 3 x 10(4) median tissue culture-infective dose of coxsackievirus intraperitoneally. On day 10 of infection, mice were randomized to receive either indomethacin or normal saline solution for 10 days, and 10 mice from each group were killed on days 20 and 30 of infection. Heart weight and size and serum atrial natriuretic peptide were similar in both groups on days 20 and 30. On day 20, pathologic scores for the degree of inflammation and necrosis were 1.7 and 1.0 for the indomethacin group versus 1.4 and 1.7 for the saline solution group. On day 30, pathologic scores were 0.3 and 0.6 for the indomethacin group versus 0.5 and 0.6 for the saline solution group. In addition, mineralization was absent in indomethacin-treated animals on day 20 after infection, but it was present in half of the control animals at that time. The degree of mineralization did not differ on day 30 between the two groups. These findings suggest that indomethacin given in the late phase of coxsackievirus myocarditis has no deleterious effects at 30 days.
先前的研究表明，在实验性心肌炎早期给予吲哚美辛可能会加剧疾病进程。尚不清楚该药物晚期给药是否安全。因此，研究了在柯萨奇病毒B3小鼠心肌炎晚期给予吲哚美辛的效果。40只3周龄的CD1小鼠每只腹腔注射3×10(4)半数组织培养感染剂量的柯萨奇病毒。在感染第10天，将小鼠随机分为两组，分别接受吲哚美辛或生理盐水治疗10天，每组10只小鼠在感染第20天和第30天处死。在第20天和第30天，两组的心脏重量、大小和血清心钠素相似。在第20天，吲哚美辛组炎症和坏死程度的病理评分为1.7和1.0，而生理盐水组为1.4和1.7。在第30天，吲哚美辛组病理评分为0.3和0.6，生理盐水组为0.5和0.6。此外，感染后第20天，吲哚美辛治疗的动物未出现矿化，但此时对照组动物中有一半出现矿化。两组在第30天的矿化程度无差异。这些发现表明，在柯萨奇病毒心肌炎晚期给予吲哚美辛在30天时没有有害影响。
